Form 4: Sionna Therapeutics Executive Receives Stock Grant

Sentiment:

Insider Transaction (Form 4)


Charlotte Mckee, CMO and Head of R&D of Sionna Therapeutics, Inc., reported multiple transactions in common stock on September 17, 2026.

Summary

  • Grant/award: acquired 50,000 Common Stock on September 17, 2026; holds 78,415 after (Direct).
  • Grant/award: acquired 50,000 Common Stock on September 17, 2026; holds 128,415 after (Direct).
  • Grant/award: acquired 155,700 Non-Qualified Stock Option (right to buy) on September 17, 2026; holds 155,700 after (Direct).
  • Disposition to the issuer: disposed of 155,700 Non-Qualified Stock Option (right to buy) on September 17, 2026 (Direct).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.

Insider Transactions

Charlotte Mckee — Officer (CMO and Head of R&D)

DateTransactionSecuritySharesPriceValueHeld After
2026-09-17Grant/awardCommon Stock50,000——78,415
2026-09-17Grant/awardCommon Stock50,000——128,415
2026-09-17Grant/awardNon-Qualified Stock Option (right to buy)155,700——155,700
2026-09-17Disposition to the issuerNon-Qualified Stock Option (right to buy)155,700——0

Key Dates

DateDescription
2026-09-17Grant/award (50,000 shares)
2026-09-17Grant/award (50,000 shares)
2026-09-17Grant/award (155,700 shares)
2026-09-17Disposition to the issuer (155,700 shares)

Keywords

insider transaction, Form 4, SION, Sionna Therapeutics, Inc., neutral, Charlotte Mckee

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.